Literature DB >> 17021637

Treatment of localized prostate cancer.

Bulent Akduman, E David Crawford.   

Abstract

This article provides an overview of treatment of localized prostate cancer, which was discussed in detail in the second scientific session of the 16th International Prostate Cancer Update. The role of radical prostatectomy in localized disease was presented by Bob Djavan, MD. Benefits and risks of radical prostatectomy were addressed by Gerald Chodak, MD. Robert E. Donohue, MD, presented the role of radical prostatectomy in Gleason grade 8, 9, and 10 tumors. Impact of positive margins on outcomes after radical prostatectomy was presented by James A. Eastham, MD. E. David Crawford, MD, provided an overview of the role of targeted therapy. Indications and results of brachytherapy were presented by Mack Roach, III, MD. Finally, Michael J. Manyak, MD, described the evolution of radioimmunoscintigraphy and clinical outcomes data.

Entities:  

Year:  2006        PMID： 17021637      PMCID： PMC1578714     

Source DB:  PubMed          Journal:  Rev Urol        ISSN： 1523-6161


  10 in total

1.  Radical prostatectomy versus watchful waiting in early prostate cancer.

Authors:  Anna Bill-Axelson; Lars Holmberg; Mirja Ruutu; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Christer Busch; Stig Nordling; Hans Garmo; Juni Palmgren; Hans-Olov Adami; Bo Johan Norlén; Jan-Erik Johansson
Journal:  N Engl J Med       Date:  2005-05-12       Impact factor: 91.245

2.  Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial.

Authors:  F Montorsi; G Guazzoni; L F Strambi; L F Da Pozzo; L Nava; L Barbieri; P Rigatti; G Pizzini; A Miani
Journal:  J Urol       Date:  1997-10       Impact factor: 7.450

3.  Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: results of the CaPSURE database.

Authors:  M S Litwin; D P Lubeck; J M Henning; P R Carroll
Journal:  J Urol       Date:  1998-06       Impact factor: 7.450

4.  Outcome of patients with Gleason score 8 or higher prostate cancer following radical prostatectomy alone.

Authors:  Badar M Mian; Patricia Troncoso; Koji Okihara; Viju Bhadkamkar; Dennis Johnston; Adriana O Reyes; R Joseph Babaian
Journal:  J Urol       Date:  2002-04       Impact factor: 7.450

5.  Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens.

Authors:  Peter Swindle; James A Eastham; Makoto Ohori; Michael W Kattan; Thomas Wheeler; Norio Maru; Kevin Slawin; Peter T Scardino
Journal:  J Urol       Date:  2005-09       Impact factor: 7.450

6.  Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.

Authors:  Liang Cheng; Timothy D Jones; Haiqun Lin; John N Eble; Gordon Zeng; Matthew D Carr; Michael O Koch
Journal:  J Urol       Date:  2005-12       Impact factor: 7.450

7.  The prognostic significance of Gleason Grade in patients treated with permanent prostate brachytherapy.

Authors:  Louis Potters; Rosemary Purrazzella; Sheryl Brustein; Paul Fearn; David Huang; Steven A Leibel; Michael W Kattan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-07-01       Impact factor: 7.038

8.  Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens.

Authors:  James A Eastham; Michael W Kattan; Elyn Riedel; Colin B Begg; Thomas M Wheeler; Claudia Gerigk; Mithat Gonen; Victor Reuter; Peter T Scardino
Journal:  J Urol       Date:  2003-12       Impact factor: 7.450

9.  Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE).

Authors:  Matthew R Cooperberg; Deborah P Lubeck; Shilpa S Mehta; Peter R Carroll
Journal:  J Urol       Date:  2003-12       Impact factor: 7.450

10.  Return of nocturnal erections and erectile function after bilateral nerve-sparing radical prostatectomy in men treated nightly with sildenafil citrate: subanalysis of a longitudinal randomized double-blind placebo-controlled trial.

Authors:  Andrew R McCullough; Laurence A Levine; Harin Padma-Nathan
Journal:  J Sex Med       Date:  2007-12-14       Impact factor: 3.802
  10 in total
  3 in total

1.  The absolute tumor-capsule contact length in the diagnosis of extraprostatic extension of prostate cancer.

Authors:  Kulyada Eurboonyanun; Nisanard Pisuchpen; Aileen O'Shea; Rita Maria Lahoud; Isha D Atre; Mukesh Harisinghani
Journal:  Abdom Radiol (NY)       Date:  2021-03-26

2.  STAT5A/B Blockade Sensitizes Prostate Cancer to Radiation through Inhibition of RAD51 and DNA Repair.

Authors:  Cristina Maranto; Vindhya Udhane; David T Hoang; Lei Gu; Vitali Alexeev; Kareem Malas; Karmel Cardenas; Jonathan R Brody; Ulrich Rodeck; Carmen Bergom; Ken A Iczkowski; Ken Jacobsohn; William See; Sara M Schmitt; Marja T Nevalainen
Journal:  Clin Cancer Res       Date:  2018-02-26       Impact factor: 12.531

3.  Knocking Down TMPRSS2-ERG Fusion Oncogene by siRNA Could be an Alternative Treatment to Flutamide.

Authors:  Giorgia Urbinati; Isabelle de Waziers; Mateja Slamiç; Tobias Foussignière; Hafiz M Ali; Didier Desmaële; Patrick Couvreur; Liliane Massaad-Massade
Journal:  Mol Ther Nucleic Acids       Date:  2016-03-29       Impact factor: 10.183
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.